Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-05-21

No results posted yet for this study

Summary

Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, single-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be a peanut. The total of participants in the clinical study will be 110, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.

Conditions

Interventions

DRUG

Omalizumab

Omalizumab is injected every 2 to 4 weeks

DRUG

Dupilumab

Dupilumab is injected every 2 weeks combination, or placebo.

OTHER

Placebo

Placebo is injected every 2 to 4 weeks

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH
  • Food Allergy Research & Education

    collaborator OTHER
  • Harvard School of Public Health (HSPH)

    collaborator OTHER
  • Stanford University

    lead OTHER

Principal Investigators

  • Rebecca S Chinthrajah, M.D. · Sean N Parker Center for Allergy and Asthma Center at Stanford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-05
Primary Completion
2025-04-15
Completion
2025-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03679676 on ClinicalTrials.gov